Neurotoxicity after CTL019 in a pediatric and young adult cohort

Annals of Neurology

Volumn 84, Issue 4, 2018, Pages 537-546

  Gofshteyn, Jacqueline S ^a   Shaw, Pamela A ^b   Teachey, David T ^a   Grupp, Stephan A ^a   Maude, Shannon ^a   Banwell, Brenda ^a   Chen, Fang ^b   Lacey, Simon F ^b   Melenhorst, Jan J ^b   Edmonson, MacKenzie J ^b   Panzer, Jessica ^a   Barrett, David M ^a   McGuire, Jennifer L ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; TISAGENLECLEUCEL T;

ADOLESCENT; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TOXICITY AND INTOXICATION; YOUNG ADULT;

ADOLESCENT; ANTIGENS, CD19; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEUROTOXICITY SYNDROMES; RECEPTORS, ANTIGEN, T-CELL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85053850697     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.25315     Document Type: Article

References (39)

1. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733
2. Lee DW, Barrett DM, Mackall C, et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012;18:2780–2790
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517–528
4. Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter Main Street and Wall Street. J Immunol 2015;195:755–761
5. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017;129:3322–3331
6. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014;20:119–122
7. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154–5157
8. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–448
9. Santomasso B, Park JH, Riviere I, et al. Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008). Neurology 2018;90(15 suppl). Available at: accessed 4/15/18
10. Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404–1419
11. Davila ML, Sauter C, Brentjens R. CD19-targeted T cells for hematologic malignancies: clinical experience to date. Cancer J 2015;21:470–474
12. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664–779
13. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388–398
14. Sadelain M. From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction. Cancer J 2014;20:105–106
15. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–1517
16. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518
17. Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 2018;11:35
18. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6. Accessed 10/9/2013
19. Zou H, Hastie T. Regularization and variable selection via the elastic net. Retrieved from: https://web.stanford.edu/~hastie/Papers/B67.2%20(2005)%20301-320%20Zou%20&%20Hastie.pdf
20. Friedman J, Tibshirani R, Hastie T. The elements of statistical learning: data mining, inference, and prediction. New York, NY: Springer, 2001
21. Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014;26:43–49
22. Deangelo DJ, Ghobadi A, Park JH, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET study). Presented at the 32nd Annual SITC Meeting, National Harbor, M.D., U.S.A (2017)
23. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T‑cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 2017;15:47–62
24. Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL”. Nat Rev Clin Oncol 2018;15:218
25. Dunne J, Lynch S, O'Farrelly C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001;167:3129–3138
26. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11:762–774
27. Shi F-D, Ljunggren H-G, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011;11:658–671
28. Hao J, Liu R, Piao W, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010;207:1907–1921
29. Lunemann A, Lunemann JD, Roberts S, et al. Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition. J Immunol 2008;181:6170–6177
30. Lunemann JD, Munz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis? Brain 2008;131(pt 7):1681–1683
31. Durafourt BA, Moore CS, Zammit DA, et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012;60:717–727
32. Cherry JD, Olschowka JA, Banion MKO. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014;11:1–15
33. London A, Cohen M, Schwartz M. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 2013;7:1–10
34. Orihuela R, Mcpherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol 2016;173:649–665
35. Shinoda K, Sun X, Oyamada A, et al. CD30 ligand is a new therapeutic target for central nervous system autoimmunity. J Autoimmun 2015;57:14–23
36. Wang W-Y, Tan M-S, Yu J-T, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med 2015;3:136
37. Carlson NG, Wieggel WA, Chen J, et al. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999;163:3963–3968
38. Downen M, Amaral TD, Hua LL, et al. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999;28:114–127
39. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994;6:341–360